Brief: scPharmaceuticals Q4 Revenue USD 12.15 Million Vs. IBES Estimate USD 12.1 Million
Mar 19 (Reuters) - scPharmaceuticals Q4 income from operations USD -16.343 million vs. IBES estimate USD -16.4 million. Q4 basic EPS USD -0.35 Q4 net income USD -18.845 million vs. IBES estimate USD -16.6 million Q4 operating expenses USD 28.493 million